Literature DB >> 6203396

Long-term follow-up after palliative operation for univentricular heart.

D S Moodie, D G Ritter, A H Tajik, D C McGoon, G K Danielson, W M O'Fallon.   

Abstract

Data are presented from 84 patients (45 males, 39 females), aged 6 days to 25 years (mean 10 years), with univentricular heart who underwent a palliative surgical procedure. The mean follow-up period was 5 years (range 1 month to 25 years). Of the 84 patients, 33 died and 51 are alive. The survivors were 1.5 to 41 years (mean 15). Systemic pulmonary artery shunts alone were performed in 43 patients, pulmonary artery banding in 15, and a combination of procedures in 26. Five years after diagnosis, 70% of patients with type A and 54% with type C univentricular heart were alive, with no statistical difference in survival between the patient groups. Because of the high attrition rate in these patients despite palliation, further attempts to perfect corrective surgery appear justified.

Entities:  

Mesh:

Year:  1984        PMID: 6203396     DOI: 10.1016/0002-9149(84)90595-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

Review 1.  [Arrhythmias in patients with congenital heart disease and their impact on prognosis].

Authors:  J Hebe; G Krings; P Hansen; M Volkmer; F Ouyang; K H Kuck
Journal:  Herz       Date:  1999-06       Impact factor: 1.443

2.  The Fontan procedure in adults.

Authors:  G R Veldtman; A Nishimoto; S Siu; M Freeman; P M Fredriksen; M A Gatzoulis; W G Williams; G D Webb
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

3.  Surgical palliation of cardiac malformations associated with right isomerism.

Authors:  T Kawai; Y Wada; T Enmoto; S Nakajima; K Nishiyama; K Kitaura; S Sato; T Oka
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

Review 4.  Surgical outcomes in complex adult congenital heart disease: a brief review.

Authors:  Alice Chan; Amna Aijaz; Ali N Zaidi
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.